On 10 October 2012, orphan designation (EU/3/12/1055) was granted by the European Commission to Topotarget A/S, Denmark, for belinostat for the treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic / disseminated).
The sponsorship was transferred to Onxeo DK Filial af Onxeo S.A., Frankrig, Denmark, in June 2015.
Treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated)
|Orphan designation status||
|EU designation number||
|Date of designation||
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: